Moleculin's Annamycin shows strong physician adoption potential in R/R AML study
Independent market research found oncologists reported 6 out of 7 likelihood to prescribe Annamycin for relapsed/refractory AML, citing efficacy, safety, and biomarker-agnostic use. Payers also expressed support for the drug as addressing significant unmet medical need in this patient population.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day